Oncopeptides Welcomes New Board Member - Luigi Costa

Stockholm (ots/PRNewswire) -

Mr Costa, currently CEO of Nordic Nanovector ASA, a biotech
company focused on the development of innovative treatments in
hematology and oncology, brings to Oncopeptides more than 20 years'
experience in the international pharmaceutical and biotech industry.
Prior to his current position, he was Vice President of Europe,
Middle East and Africa for Onyx Pharmaceuticals Inc. where he led the
company's international organization and the launch of its multiple
myeloma drug Kyprolis® outside the USA.

Prior to joining Onyx Pharmaceuticals, Mr. Costa held various
leadership positions at Amgen, including Head of International
Oncology Franchise, General Manager of Amgen Italy and President of
Amgen France, the company's then largest market outside the USA. He
has also held various leadership positions with Eli Lilly both in
Europe and America.

"Luigi further strengthens the Board's breadth of talent; he
brings valuable international development and commercialization
experience in the hematology/oncology area in general and in multiple
myeloma specifically. We are delighted to welcome such an outstanding
individual to the Board" said Alan Hulme, Chairman of Oncopeptides.

Mr Costa commented: "I am delighted to join Oncopeptide's Board
and to have the opportunity to contribute to the Company's
development at such an important stage. Multiple myeloma is a very
severe disease and looking at the phase II data, melflufen represents
significant promise for patients. I look forward to working with the
Board and management and applying my experience to help maximize the
Company's potential."

Multiple myeloma is the second most common hematological cancer. In
2016 it is estimated that in the US there will be 30,330 new cases,
with an estimated 12,650 people dying from the disease[1], which
carries a five-year survival rate of 48.5%[1].
About Oncopeptides AB

Oncopeptides is a clinical stage pharmaceutical company developing
oncology therapies centered around peptidase targeting.

Melflufen - Oncopeptides' lead compound in clinical development -
is a peptidase targeted therapy and a potent anti-angiogenic
compound. It triggers rapid, robust and irreversible DNA damage and
manifests its cytotoxicity through alkylation of DNA.

Many peptidases that are overexpressed in cancer cells, such as
tumor cells in multiple myeloma, cleave melflufen so that the
concentration of active compound increases in the malignant cells.
This results in targeted delivery of the molecule and more effective
treatment of the disease.

Oncopeptides is currently concluding a Phase II clinical trial
with melflufen in patients with relapsed and relapsed-refractory
multiple myeloma. The study is being carried out across seven
centers: in Denmark, Italy, the Netherlands, Sweden and the US (three
centers) - with Dana Faber Cancer Institute, Boston, MA being the
lead investigator site.

[1] National Cancer Institute. Surveillance, Epidemiology and End
Results Program. http://seer.cancer.gov/statfacts/html/mulmy.html .
Accessed June 07, 2016.

ots Originaltext: Oncopeptides AB
Im Internet recherchierbar: http://www.presseportal.de

Contact:
, contact:
Jakob Lindberg, CEO
Tel: +46(0)-705-695-471
Email: jakob.lindberg@oncopeptides.se
Web: http://www.oncopeptides.se